Veru Targets GLP-1 Muscle Loss Risk With New Enobosarm Combo Study

Veru Inc (VERU) announced an update on their ongoing clinical study.

Veru Inc. is launching a Phase 2b proof of concept trial called PLATEAU to test whether adding its oral drug enobosarm to semaglutide can improve total body weight and physical function in people using GLP-1 drugs for weight loss. The study matters because it targets a key gap in the obesity drug market, where rapid weight loss can come with muscle loss and weaker mobility.

The trial tests two drug combinations in adults with obesity or overweight and mobility issues. One group gets semaglutide plus enobosarm, while the other gets semaglutide plus a placebo, aiming to see if enobosarm can help keep muscle while still cutting fat.

This is a randomized study, so participants are assigned by chance to each group, which helps reduce bias. It is triple blind, meaning patients, doctors, and study staff do not know who gets enobosarm or placebo, and the main goal is to treat weight and function issues, not just to observe them.

The study was first submitted on February 25, 2026 and is listed as not yet recruiting, so patient enrollment has not started. The most recent update was filed on March 9, 2026, and final completion and primary readout dates are not yet posted, highlighting that the trial is still at an early stage.

For investors, the update signals Veru’s push into the booming GLP-1 ecosystem, positioning enobosarm as a possible add-on to block muscle loss in patients on drugs like Wegovy. A positive readout could support a higher valuation for VERU and attract attention from large obesity players such as Novo Nordisk and Eli Lilly that may seek combo or licensing strategies.

Near term, the impact on VERU’s share price may be sentiment-driven, with traders reacting to trial progress and any partnership chatter rather than revenue forecasts. The trial also underscores growing investor focus on second-wave obesity solutions that improve quality of weight loss, not just the scale number, which could favor niche players that complement, rather than compete with, GLP-1 leaders.

The PLATEAU study is currently listed as not yet recruiting and remains active in setup, with additional details and ongoing updates available on the ClinicalTrials portal.

To learn more about VERU’s potential, visit the Veru Inc drug pipeline page.